A Case Study in the IBS-C Management Continuum: Assessing Patient Response and Tailoring Treatment.
作者信息
Ahuja Nitin K
机构信息
Associate Professor of Clinical Medicine Director, Program in Neurogastroenterology and Motility Division of Gastroenterology and Hepatology University of Pennsylvania Philadelphia, Pennsylvania.
出版信息
Gastroenterol Hepatol (N Y). 2024 Jul;20(7):383-427.
Abstract
摘要
相似文献
1
A Case Study in the IBS-C Management Continuum: Assessing Patient Response and Tailoring Treatment.肠易激综合征便秘型管理连续统一体的案例研究：评估患者反应并调整治疗方案
Gastroenterol Hepatol (N Y). 2024 Jul;20(7):383-427.
2
Patients' perspectives on GP interactions after cognitive behavioural therapy for refractory IBS: a qualitative study in UK primary and secondary care.患者对难治性 IBS 认知行为治疗后全科医生互动的看法：英国初级和二级保健中的定性研究。
Br J Gen Pract. 2018 Sep;68(674):e654-e662. doi: 10.3399/bjgp18X698321. Epub 2018 Jul 30.
3
Cognitive and Behavioral Differences Between Subtypes in Refractory Irritable Bowel Syndrome.难治性肠易激综合征亚型之间的认知和行为差异。
Behav Ther. 2019 May;50(3):594-607. doi: 10.1016/j.beth.2018.09.006. Epub 2018 Sep 21.
4
Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Irritable Bowel Syndrome with Constipation (BURDEN IBS-C) Study: Results of an Online Questionnaire.更好地理解和认识便秘型肠易激综合征（BURDEN IBS-C）患者的脱节、体验和需求研究：在线问卷结果。
Adv Ther. 2018 Jul;35(7):967-980. doi: 10.1007/s12325-018-0733-x. Epub 2018 Jun 26.
5
Chronic Constipation and Constipation-Predominant IBS: Separate and Distinct Disorders or a Spectrum of Disease?慢性便秘和以便秘为主型肠易激综合征：是单独且不同的疾病还是疾病谱？
Gastroenterol Hepatol (N Y). 2016 Mar;12(3):171-8.
6
Assessing the post-treatment therapeutic effect of tongxie in irritable bowel syndrome: A randomized controlled trial.评估痛泻要方治疗肠易激综合征的治疗后疗效：一项随机对照试验。
Complement Ther Med. 2022 Sep;68:102839. doi: 10.1016/j.ctim.2022.102839. Epub 2022 Apr 26.
7
Treatment patterns, symptom reduction, quality of life, and resource use associated with lubiprostone in irritable bowel syndrome constipation subtype.与鲁比前列酮治疗肠易激综合征便秘亚型相关的治疗模式、症状减轻、生活质量及资源利用情况
Curr Med Res Opin. 2016 May;32(5):899-905. doi: 10.1185/03007995.2016.1150262. Epub 2016 Mar 11.
8
The Neutrophil-to-Albumin Ratio (NAR): A Novel Index in Relation to Clinical Symptoms, Quality of Life, and Psychological Status in Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D).中性粒细胞与白蛋白比值（NAR）：腹泻型肠易激综合征（IBS-D）中与临床症状、生活质量及心理状态相关的一项新指标。
J Inflamm Res. 2024 Jun 10;17:3685-3695. doi: 10.2147/JIR.S458363. eCollection 2024.
9
Improved work productivity and health-related quality of life in patients with irritable bowel syndrome with diarrhea receiving eluxadoline following inadequate response to loperamide.在对洛哌丁胺治疗反应不足的腹泻型肠易激综合征患者中，接受埃鲁索多林治疗后，患者的工作效率和健康相关生活质量得到提高。
J Manag Care Spec Pharm. 2021 Apr;27(4):469-477. doi: 10.18553/jmcp.2021.27.4.469.
10
Physical activity for treatment of irritable bowel syndrome.体力活动治疗肠易激综合征。
Cochrane Database Syst Rev. 2022 Jun 29;6(6):CD011497. doi: 10.1002/14651858.CD011497.pub2.
本文引用的文献
1
Managing IBS-C: Focus on Symptom Control.管理便秘型肠易激综合征：关注症状控制。
Gastroenterol Hepatol (N Y). 2024 Apr;20(4):216-226.
2
Mechanism of Action Considerations in the Management of IBS-C.IBS-C管理中的作用机制考量
Gastroenterol Hepatol (N Y). 2023 Dec;19(12):749-756.
3
Patient-Reported Outcomes in Disorders of Gut-Brain Interaction.肠脑互动障碍的患者报告结局。
Gastroenterology. 2024 Apr;166(4):572-587.e1. doi: 10.1053/j.gastro.2023.11.307. Epub 2024 Feb 1.
4
A Diagnosis of Irritable Bowel Syndrome Using Rome IV Criteria and Limited Investigations is Durable in Secondary Care.采用罗马 IV 标准和有限检查对肠易激综合征进行诊断在二级保健中具有持久性。
Clin Gastroenterol Hepatol. 2023 Dec;21(13):3397-3404.e1. doi: 10.1016/j.cgh.2023.05.022. Epub 2023 Jun 9.
5
AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Constipation.AGA 临床实践指南：便秘型肠易激综合征的药物治疗管理。
Gastroenterology. 2022 Jul;163(1):118-136. doi: 10.1053/j.gastro.2022.04.016.
6
Inflammatory and Microbiota-Related Regulation of the Intestinal Epithelial Barrier.肠道上皮屏障的炎症与微生物群相关调节
Front Nutr. 2021 Sep 13;8:718356. doi: 10.3389/fnut.2021.718356. eCollection 2021.
7
Systematic review and network meta-analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation.系统评价与网状Meta分析：已获许可药物治疗便秘型肠易激综合征腹胀的疗效
Aliment Pharmacol Ther. 2021 Jul;54(2):98-108. doi: 10.1111/apt.16437. Epub 2021 Jun 11.
8
Bisacodyl: A review of pharmacology and clinical evidence to guide use in clinical practice in patients with constipation.比沙可啶：药理学和临床证据综述，以指导便秘患者临床实践中的应用。
Neurogastroenterol Motil. 2021 Oct;33(10):e14123. doi: 10.1111/nmo.14123. Epub 2021 Mar 9.
9
Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 26-Week, Placebo-Controlled Phase 3 Trial (T3MPO-2).Tenapanor 治疗便秘型肠易激综合征患者的疗效：一项 26 周、安慰剂对照的 3 期试验（T3MPO-2）。
Am J Gastroenterol. 2021 Jun 1;116(6):1294-1303. doi: 10.14309/ajg.0000000000001056.
10
ACG Clinical Guideline: Management of Irritable Bowel Syndrome.ACG 临床指南：肠易激综合征的管理。
Am J Gastroenterol. 2021 Jan 1;116(1):17-44. doi: 10.14309/ajg.0000000000001036.
Zotero 插件